Journal article
Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study
Abstract
Eight multiple myeloma patients participated in a phase I trial evaluating the feasibility and safety of subcutaneous vaccination with adenovirus engineered, autologous plasma cells after high-dose therapy. Plasma cells were concentrated from bone marrow harvests by negative selection and high gradient magnetic separation. The mean plasma cell yield was 2.61 × 108. Transgene expression measured 48 h after plasma cell infection with an IL-2 …
Authors
Trudel S; Li Z; Dodgson C; Nanji S; Wan Y; Voralia M; Hitt M; Gauldie J; Graham F; Stewart A
Journal
Leukemia, Vol. 15, No. 5, pp. 846–854
Publisher
Springer Nature
Publication Date
May 1, 2001
DOI
10.1038/sj.leu.2402077
ISSN
0887-6924